SRTS - Earnings call 4 2023 | Sensus Healthcare, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Sensus Healthcare Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Kim Golodetz. Please go ahead.

Kim Golodetz

Thank you, operator. This is Kim Golodetz with LHA. participating call. for all you in today's Thank

Joining and President Chief Sensus Healthcare Officer. and Sardano, Chairman are Joe Financial Executive Chief Counsel; Javier me and from General Rampolla, Officer; Michael Sardano,

statements management's expressions as of a contain based believes, Sensus no as laws. the undertakes XX-K should Healthcare address future call within February will, All the described All law. are uncertainties As other statements forward-looking statements other are required as conference or some and matters will anticipates historical during Forms XXXX. XX-Q. forward-looking information forward-looking federal be X, of are currently meaning obligation occur expects, of activities than to may The to assumes, by intends of call, in that except this risks and statements beliefs the and statements forward-looking plans, today's forward-looking discussed securities in on similar revise Healthcare or available that subject reminder, company's facts or Sensus the the date any update statements.

the accordance Joe? turn substitute results to press financial will today's GAAP. substitute made should for be that to A I'd During they references results for is viewed determined not a yet measures. as like provide useful included in with to be these nor GAAP call, release. to information investors, operating financial certain over should considered be Sensus for in today's reconciliation GAAP results believes Joe of non-GAAP a said, call non-GAAP With measures as they Sardano.

Joseph Sardano

everyone. afternoon, good and Kim, you, Thank

of including and keloids. number we United brings to States. the as This substantially XX of patient SRT compelling well the quarter, shipped total shipped acclamation XX Sales SRT units. cancer to treat outcomes as non-melanoma financial our proposition quarter units in fourth their inflationary an customers' outside during systems better Our X environment the results of skin to and reflects XXXX systems as the understanding financial improved

installation approaching XXX We are systems. unit a total fast of

ago, were For than $XX.X QX, threefold sequentially. revenues million year $XX.X million up more a versus

in strongest by We are increase. population skin seasonally our reimbursement if uptick utilization being results and not surgery. driven cancer and than good, utilization most expect SRT an treat clinical the aging at least of quarter, non-melanoma continues is to favorable This to fourth increased as as better, that

have For ways for alike to quite practices. time, SRT their prospects been to some new and customers add asking

our we're lease, needs As always, our offering. provides value we SRT This and to listen which market by in highly equipment XXXX. recall fair Sensus our with was you'll dermatology This which market and capital to revenue expands option viable to enhanced their complements model, with model another to closely we delighted meet new providing competitive introduced bring practices. recurring market, our sales model revenue to recurring new

quarter, During for placement Vision with revenue Sensus and the laws model we year, all and model. I've guided capabilities better is allows also ideal clinics to this for asset make health utilization managing SRT-XXX time. of mentioned quarterly management first This we've and image customers and previous track compliance past software billing work Note clinical preparing the that exclusive. applicable a with real utility This that and now calls our for the made we regulations. ensuring economics recurring our making that by recurring revenue of ultrasound possible. under over that the abiding on technology, Sentinel and were fourth this sure this and is carefully may Sentinel. We've customers our both census also role you our advanced excited a for is technology been the growth, been technology so HIPAA in our all to us dermatology is in why play expected care key understand model with

earlier can resolution an growth Should directly surveys we treatment after SRT benefiting become in high-resolution treat lesion rates outcomes that looking the the technology the from we've lesion to treatment. experienced This XX% will SRT rate the X seen. new the We're provide we great of treatment Recall XXXX, to growth and physician continue, forward the more of on improved years also clinical XXXX, in during treatment today rate and in soon see growth be Sensus treatment particular, prospects and During will through leads our because begins we important also to choice also and the introduced Diego, XX capability. a for we year-over-year that the Medicare actually of ultrasound SRT the see Vision found up impact interacting the our reviewed. for Cloud and each very coming San to Beach conferences strong with non-melanoma be excited weekend, very customers This We'll in the X be with IGSRT Technology held in presence. at which clinical SRT-XXX capabilities winter of Sentinel the Symposium, February where cancer. Miami. Miami weeks. Annual have Dermatology's beginning We'll South and showcasing being we'll Meeting products, at those follow skin March We're SRT in XX. system a Academy American this

oncology market, our market, mainly hospital-based is engage channel. is dermatology the we While which continue primary with to a radiation

Cod had recently at Cape good quarter, placed Hospital. As this success having we've in an SRT area, system mentioned last

As longer for respect the platelet-rich the filed we with experience. restoration as XXXX, October to are be from PRP, a applied a system in or With allow coming XXX(k) hopeful our be the this to market of in pain-free the we'll infusion see in hair scalp that and the to hearing continue plasma will, agency cycle we product, U.S. This FDA sales weeks. to application a interest. example, has transdermal reminder, increased

lens. been application hyperhidrosis In addition, presented sweat already posters have the of or overactive on

Sensus-branded includes Our Lasers. Smart IT our system solution of all do as X transdermal Sentinel capabilities aesthetic

remarks, General about with collaboration in week. to With turn call our be Directors will Michael on who, progress. dermatology last CureRays. joined the business his upcoming update over We Michael? our the works of those Board TDI and I'll exhibiting give it new duties Counsel, as addition President to shows a in our you at product trade He'll and brief our international as talk Sardano

Michael Sardano

Joe. the year both Thanks, up strategic international working approvals which to of and new last requires distributors. engagement We regulatory open territories, spent

We the namely systems to new support China. which a our XX and Ireland, Europe sold distributors demand continue East, a includes Middle in and international our to Turkey. across sales in Guatemala of developing Asia, opportunities to are strong of year, territories Sensus during XXXX, We we total SRT internationally for and promising X the number supplement

highly earnings plan our Latin last as as Japan and American, our Brazil to as is As regulated. and I being Asian stated November, in in expand they European our footprint quickly prospects with call longer-term are possible

to open X is goal achieved new X per which territories we year, in XXXX. Our to

University financial an be oncologists, Oncology conducting Atlanta Turning Health keloids, is at SRT the focused the on with dermatology the for and back Sensus' X TRAs treatment Sensus Vice customers at collaboration who be CureRays. Radiation their purchased led Emory to for radiation and in trials and treating patients is Memorial vision CureRays California use of Hess, announced Dr. the a clinical With will a Director is U.S. market. Sensus' endeavors, X this has be are to Mohammad cancer model, results. discussion who week, Javier Sierra CureRays instrumental patients Board them. headquarters. the is by call oversight non-melanoma revenue our will of CureRays Hospital our California. Earlier to main we very Clayton I'll Chair of SRT-XXX out on turn with of partnering in and is Education for the Nevada reoccurring excited of Dignity with Khan, for to and Dr. we technology. that, over treatment and skin Advisory Medical

Javier Rampolla

and afternoon, everyone. Michael, Thanks, good

compensation of for expense of and lower to offset for attributable for year for sold. and As quarter for in of with aesthetic Joe higher prior of the revenues revenues million fourth with revenues decrease sold year primarily decrease compared $X.X of expense million quarter in trade XX.X% partially $XX.X due XX.X% The the a reflects is quarter XXXX The the in completion margin by quarter. decrease General the number There due the quarter $X.X show XXXX. for expense, of prior were third million compares and year to due units the last $X was million with million, XXXX same gross expense quarter amenities or $X.X XXXX. for million expense ago debt million quarter of million quarter a units primarily for costs. compared the lower was was profit compared with the fourth was drug delivery revenues in number fourth $XX.X The was expense mentioned, decrease $X.X bad XXXX with quarter fourth lower of of of primarily of the compensation was system the of XXXX. of of fourth quarter. development quarter fourth of to year. $X.X profit XXXX. XXXX the lower and XXXX or Research for million market. in quarter and a The million the to of fourth the was $X.X The the the million development of higher $X.X compared XXXX a Gross was SRT our the quarter $X.X versus this of revenues decrease fourth XXXX

net and depreciation, XXXX, We income EBITDA, for of quarter was diluted XXXX. a Other expense XXXX. unchanged XXXX and work for interest to compares fourth quarter up $X.X income the share, million diluted U.S. quarter taxes, the of have of interest, have Food project. fourth of of Net for the million from of $X.X mostly from for earnings was the or fourth the submitted was XXXX this $X.X per before quarter per on the most for which fourth $X.XX XXX(k) fourth compensation share quarter we income was the $X.XX define with and and Drug million $X.X million as of of quarter application Adjusted XXXX. and million related this completed Administration stock $X.X the to or income fourth amortization of

XXXX. with $XX.X net the $X.X increase compensation in with for use. vendors me gain to reflecting Other net of sale expenseâ€¦. was XXXX XXXX income with of the income compared for units income units delivery increase $XX.X customer lower $XX.X XXXX for million compared Other income. compared XXXX million $XX.X million expense results million or Net the to for XXXX. with expenses. for or $X.X for by by million the gain Gross million XXXX. XXXX number largely full deferred $X.XX and show or and Let XXXX in for and sales XX of diluted the million the administrative share, million drug of $X for a compensation XXXX, million of for for $X.X profit for related a or of and year [ due reflecting for interest macroeconomic income higher years... sale purchases net due with was sale of for higher Net for Selling a our costs charged on revenues trade was XX.X% XXXX $XX.X XX.X% million related $X.X million asset. highlights. of few customers the General XXXX a touch financial XXXX, due million diluted million of aesthetic $XX.X to million as with for for sold $XX.X on lower income primarily this XXXX and noncore of per million to a was XXXX out $X.X $X.XX marketing $XX.X lower number revenues with to XXXX per sold conditions with development EBITDA expense R&D were compared was fees reflecting lower system asset. on share. of was compared Adjusted XXXX mostly of Revenues related million $X.X offset higher was $X $XX.X noncore expense expense $X.X compares for includes ] for professional XXXX, compared with XXXX and million to to million a was

as for Turning $XX.X amount its now The XXXX equivalents credit during $XX.X and in any of finished to $X.X XXXX the and especially the year-end XXXX. of to inventory of cash outstanding ahead million, price of XXXX and recurring increases XX, our prepaid part revolving as models. end year-end XXXX. above December million $X.X or borrowings Cash versus XX, well built at of had anticipated versus inventories was as XXXX. December At to of no balance goods were $XX.X earlier for from company million Prepaid million prepare get XXXX, growth, of million the as We've end XXXX, million under the inventory end revenue the of XXXX. sheet. and were at $X materials of

very spend of advantage Nevertheless, to cash we to our create focused we the or positions growth sheet continues balance Our opportunities take may come on be across disciplined. well us ourselves. that highly company may

table we earlier As the for we see to in With reconciliation the a I'll turn final of issued non-GAAP back comment, today a to news the GAAP Joe. financial measures. that, call release

Joseph Sardano

interest. SRT model it's Michael. market under to initial early, great our being are value And and recurring continues Javier of for be fair Thanks, The leasing system with met deal our our of although premium ROI our a revenue introductions compelling. program

program sure studies or better are And SRT leaving word scar. IGS have certainly, that medical With for than surgery. surgery. There noninvasive become meetings, it's SRT as this most shown is the good many have the clinical that for the option we'll results gain and Published momentum question #X spreads. no as upcoming no I'm RT

stages cancer and enormous As we SRT, many in I've said market skin tapping just of are non-melanoma for keloids. opportunity in the the still early times,

untapped systems the of solution millions prevent market. in are well and largely for a patients Our recurrence positioned excision. arguably to alternative provide compelling only and of a large surgery following keloids the They to

non-melanoma million lifetime. of us cancer. overlay will X XX have estimated develop tells an in during cancer skin Americans X As will skin all people nearly to an this, that their This

there's need future. for and our the so clearly, SRT both systems in even now So a more

have you we're take comments, for We that those Sensus operator, attention. implement and we to time are positioned and And strategies. I ready drive your success, to team confident is growth for now a and With great thank questions. our

Operator

session. Nowak question-and-answer first now And Alex will the come with begin question Capital. Craig-Hallum will Instructions] We our from [Operator

Alexander Nowak

of hoping this possible, placed in the doing you how touch here. Okay. expand on Maybe a been Joe, I walk was it to you on make the all came economics. background together model the something you've kind could that new recurring through the work maybe

detail you're that well. CapEx more very the the we some model certainly into as venturing model know versus recurring Just

Joseph Sardano

Sure.

quite I First it it some of we were all, we've evaluating customer to years, recurring such last tell been we ask for would been you to bring the for to over that we've and this market. as X this. timing we time, prospect that sure involved right model And in our year would make wanted base to get us continued who our model, engaged to have with when base, model a recurring revenue

have And decided it time complement we other to so market, that value products right us is to this that them, a we as in into leases have we've to as in is and market existing the this listening come opportunity good the the that as fair offerings to well for well. SRT-XXX

able provide with assist. closely technology, along come could support to a customers. some with HR that people where being dermatology-based and in would And or So, that We've with model us help using working said, provided can with these and service oversight is with experts CureRays the model for and a being that the we provide customers coding help our people that independent endeavor. billing we're our

their that program necessary in Vision So, with have we practice. position SRT all provide a getting to the gives IGSRT turnkey that the choice another tools SRT-XXX we think them into

Alexander Nowak

sense. total Makes

You try might here, piece economic not want the to go the it on but anyway. for into call I'll

back under out If us normal vision, there. this around an SRT Help that pays you is will, place over something utilization

Joseph Sardano

Yes.

out for Of sides. course, work it both has to

it get generate significant see think you a over will that allow and a year. this, that target following of will it or the well. think start. And model. And think will for as for to that be recognizing before but the we can the along will be I year claim lot year, So, of that I it coming term, as start recurring it with company selling next we to an this tell year, the quarter of involved long systems revenues that probably with revenue units the installed years, I continue happening will we would revenue we for the be quarter don't awful second will incremental bunch substantial us place us, this first I I products revenues and

Alexander Nowak

Yes. model all? No the at doubt. Does change skincare the relationship

Joseph Sardano

it No, shouldn't.

an or own. have. I that is or base model think for it on didn't this prospects to the left that the well an so that where customer there with them offering go and that their this excellent very customers out year and they want they They very, seems the or works format complements the way But that were very very, SkinCure like we over an have. last one that provides doing excellent have were well alternative. of other,

So, into lot for a to us, allows that it's just play. an additional more tool prospects come

opportunity If what that value you an to fair up with lot lease, provided of the SRT-XXX we a to look SRT-XXX move customers at the did market from vision. an

it more to made And who overall IGSRT vision are is more further is we're customers this want to affordable. especially done. trying involved enhance it going to patients to get what available the looking to So, more XXX this make to do with product. more SRT-XXX, the get This

you in our So, this will, the just toolbox. adds if have, to or that the we our vocabulary, armaments tools

Alexander Nowak

our we're been going a and environment seeing it with dermatology, there. aesthetics more just questions. last cost is is turn let's months on like? there And back is in QX back, could out from bit then the cuts, of to market momentum a difficult, a cuts, in expand And stick cost ]. walk has of what's like Big to you looks to looking XX maybe just just you're here? QX lastly, be it, a bounced QX there, little going just it place back how through implemented What set maybe positive number the -- this XXXX what what call [ on a after be out then that's

Joseph Sardano

to where after had they of getting understand quarter that the Sure. into Well, and we I than actually order types I to the through and where provided what same that they better started pretty And going, those the quarter. up we first to and the mean the clear when which did we February year. quarter the it a from people doors, and a frankly, work the we they out where where said based of was And been we announced much I going. of And to customers, lot but a if we us for listening hurting of course announced the economy up market the that customers, proved at over this it that the lot AAD, early that year. we thought leading with speaking to would much fourth everything third are March the the quarter, coming our market you that little believe required, of exactly first, was think less we guidance the as coming second inflation we forecasted their we then got recall, happen and lot by conferences them. we were after And this at for that the as those on people. how think meetings again proved thanks impacted first were was and year people had in was business a where on pretty time, and quite out Not think I meetings were. in was was getting then And that it following and cash aesthetics we

is of does sales we're far product we continue anybody. beyond new So Well, up I we're a have the quarter for because products the course, to year space to how of think take with versus first that We're because momentum. are install. also to buy share model, look more for as the with lot to having and excitement revenues going we going a to lot lead it's as think year which ended great introducing I the moving some we taking into this think to a people as XXXX? going on But new of to going

it is it's can't what And $X there's And show base FDA and progress. works in we I think bring clearance on really, some or with I $X generate that, more give can it identifying product, whole really you're lot million for we're FDA good some the of flexibility going hard revenue. TDI potential pushing the But sell the we're get going to to we're it then for revenue us really customers interest We it's or -- it. we're lot to and gaining as push to think We what a offering. a predicting is in looking at entire million for year. once that that.

more being yes, there's that These inflation. away, about we that hope and all we an are more patients that we're So, we long with in generate to the SRT. We are going to to in SRT, on election have enthusiastic all term the hope participate all is because of in control. which we're doing middle more to being Take said, revenue no that that, that and short more us. no want have they're strike. for done We're treatments means there's year. to And can't what access that world things and going more going and more that

doctors go with to to operation customer the SRT type ourselves that almost is turnkey skin recognize of exists. acquire they skin for to a need that total-solutions, around our they So, cancer I are SRT cancer because fact, that establishing we're every treat because address too, think amount just not for to instance the there of enough looking

increase. that the we top now going looking that on excited at all it's we're possibly including revenue continue So, get, recurring to can that service to on we're of revenues hit points revenues

disciplined And I going we extremely expenses, And that very have. years us And be execute and as team we've say that's been even have as disciplined our about it. more kept months enthusiastic and as think I'm so, mature days and Javier and those thank entire the just headed and again, to continue always go extremely by to on. to we're about disciplined go on going drive the we and on we're I the to that

overall way. again, every in overexcited So we're

Alexander Nowak

great the to hear. Appreciate update. It's

Joseph Sardano

No. Alex. Thank you,

Operator

And our next question Chen H.C. come will with Yi from Wainwright.

Yi Chen

My first is the of quarter, includes in systems recurring question the under revenue that model, shipped the number the correct? assistance

Joseph Sardano

No, doesn't. it

Yi Chen

No, it doesn't.

Okay.

Joseph Sardano

we that that units recognize revenue. were ones talked XX about

Yi Chen

Okay.

for the the overtake you model So, could revenue expect number I shipped do purchase? the systems significantly under the maybe -- of XXXX, models under recurring increase -- capital and mean, the the recurring revenue shipped potentially under systems

Joseph Sardano

selling. We another selling to system. that to We way our overtake way, equipment customers but it's going I don't just to acquire But it's going the again, Yi. our to going that don't for -- think outright, complement think not it's it's feel the

initiating you now. year I model years platform. model, would revenue this in revenue X we to units from expect recurring sell it's But year Now a tell to of don't be than more providing the I like know in going or that recurring first what still

Yi Chen

of have it. revenue to recurring CureRays? you Got any with Do share part the

Joseph Sardano

No.

Yi Chen

a many systems how Okay. at it. And to ship this in be provide to shipped rough guidance expect XXXX. can point, Got you you

Joseph Sardano

-- for to we when all year fourth to the time, I more. We're out as great really in I year always don't didn't try push happening a But how depends we well. mean this want were quarter go on it there. started such works when again, going inflation to hard. hit things this at XXXX some after big we turn expecting at But way, were that last things out.

other saying worry is under things disappoint overachieve We that rather and We better hard you very, versus did the you work and but want very makes the to don't what make that assure going to achieved in we commit anybody, I the we predicting about year than going sure to before. can it would So, things. way. everybody team

Yi Chen

under recurring place the you Got improve And it. as units more shall Okay. revenue. in the margin we gross XXXX to expect

Joseph Sardano

So I early this right the they of -- the in margins are basically will now, give way the we're at the stage program.

just developing I to them it this continue program. we'll will then -- is and So, the as continue way keep we and improve

Operator

question And Maxim will Anthony with our Group. next come Vendetti from

Anthony Vendetti

Thanks.

number So, total know a can system. into share? point final the if seeing update, for but FDA just there? obviously, what's do guess, And that But installed I the more the exactly? trends infusion in just for to your out then transdermal awaiting little is that utilization that base could you expectation approval you're approval. for we you're at systems FDA, an where up a you you dig have have I And your this that And

Joseph Sardano

one, Number Okay. we around XXX world. the products have over installations SRT of

the XXX would approve to it, in FDA April, will that process. So, lined the get I process time for of approved, start sometime in, with manufacturing hopefully, The but in If clearance FDA we units second the to beyond. like and that in we March. we've March, this hit in product sure finally getting fiscal the week closing we're by I submitted year, go get shipping up we we think in AAD we the that the we'll -- things TDI and when begun October could XXXX. And couldn't of working predict had

be to as get So, we year I in ready quarter the think that second in as of FDA long first quarter. clearance we'll ship the this

Anthony Vendetti

type just of Sentinel from physicians... system what any trends glean you're Okay. the or that great. No, you're hearing from utilization And your to that's just from able

Joseph Sardano

Yes.

XX% as continue up. Clearly, year-over-year. with we've the a in volumes past the I the same think seeing we're seen go to increase that

cancer, people seem to being of there's so the more and for and be choosing scanned And treated. that whatever more are getting they their or noninvasive way skin body

continue as sooner skin more good doctors. There's points And become a for It's that, I've stated mind, the cancer. question And to that a way. all of before, or this choice to fast for a think there's it's of going this I my cash happen. So, way. the will in non-melanoma flow a that grow. of for lot is productive trend to good It's treatment no later the #X

treatment the of choice be will it think very I shortly. very,

Anthony Vendetti

month the And many And to I of to in is Or rate, order depending it's there Great. guess, of lastly, program. fair number. large model, placement? breakeven, know just terms on placement? interest -- a it's a in market X.X%, if it obviously of then perform a they But do is the X%, revenue-sharing not treatments? to get terms a minimum on have number relatively -- the or treatments whatever the just is in how per I just Okay. recurring lease, it's treatments which

Joseph Sardano

Yes.

a tell you the buy than XX XX First of month. all, currently But we that most is a the minimum or month part. there's patients of with own not breakeven be any to have system, system the we a revenue. that X a less don't SRT patients and delivered with have doing would approximate some units a patients And I or -- recurring must although number are for that our customers a do that customers XX of patients to

some seeing we're So, sites. at very high volumes those

to doctors to are us, I clearly, profitable the them. have and come some I the think for that are come to in the going going valuation this us for to do going who of volumes. They're the to and model the we're be profitable keep patients, have money. going clearly, be their so And to of to ability going know approach that if that and decent a interested have for that to that customers agreement most that's think establish. to going lot And But we're us, model it's I going and think ones we're customers whatever we're is a they fair to to they're going the

model to So, we're forward to looking them. introducing this

this also that is if this that customers it XX on would up that worthwhile to revenue agree going they XX we recurring buying different to for model, something X them review. tell think end to I you But presentations you all is bet make be the anyway. I'll I

Anthony Vendetti

right. Right,

saying in XX some lease better the Especially the that. see a market the fair that -- patients decide Okay. a is than sharing you're on as They average, way of physicians if product than see may many and that going purchased month you're revenue. more

adoption cash the them lease some or giving which you're lay the reticent could XXXX. go necessarily out are option, So increase for route in to theoretically either the that -- rate but the

Michael Sardano

Yes.

Michael How this is Anthony. Additionally, you... are

to Part is model this operations that into going some away be that go good... standpoint taking work practices. from the an of of we're also the So

are practices of so the on they some to some of that to pay other the us areas operational work would supply personnel itself the concentrate on business. actually outside practice certain from that So willing take could away the

then supplying would we take that those So, to away work. be personnel

Anthony Vendetti

Interesting. Okay.

it. Okay. color. the I appreciate I'll Great. back That's in queue. helpful hop

Operator

from Alliance come Partners. go with will [Operator Instructions] next Our Global Please Ben Haynor ahead. question

Benjamin Haynor

You Okay. hear me

Joseph Sardano

sir. Yes,

Michael Sardano

Yes, Ben.

Benjamin Haynor

Excellent.

are a There's components just that folks for maybe that how that will how for encompass ground. for clarify, putting get does the fee of I So fee. the it model? different to into potential like there's rental, sounds click go there's that potential on personnel put -- many revenue the What together... some the recurring fee mean potential could you're ultimately

Joseph Sardano

what... the On or quarterly

Michael Sardano

Thanks Michael... for It's Ben. question. the Thanks, Yes.

component, component. device the There's it. to components X and really personnel there's there's the then So,

a to we said RTT and mainly oncologist it Anthony, the simple, the on they on way just it. a Vision. device purchase radiation these that lease the I are as physicist it's own And So, is it utilize that or personnel, They SRT-XXX these if on they would work usually their practices to do personnel and same side, for. the the would supply side

you car, Well, and have in instance, for you. I that So, a take always now Toyota an do or car that have you just to cars going to if for as used fixed. example, the to what you'd we're bought have

drive can all we aspect. standpoint and responsibility an you car In a can to have things we that do do you'd and addition, operations the normally from the for

are they're other practices with busy that so some interested in very just because things. So,

Benjamin Haynor

I helpful. had revenue model on Okay. to that have that's you haven't there you how and was we in mean the providing a sense fulfill just out been haven't personnel because able past? recurring it the the there for demand much

Joseph Sardano

had we've can people interested based you and that us about the and meetings people in with model asking getting the I this. into tell Well, that on

very very, high. the interest think I is

going So, capital the equity-backed that buy serious And very extremely I groups their about clinics. with to have make the to is is models, like to I are that presentations bigger to very, biggest these looking we're think opportunity being this and private impact use think because bigger it would to more the going be at important. model the they

able free lot be to up this. so, And their we capital a of to do

biggest going that's where is I this think opportunity our So, model. to be with

Benjamin Haynor

moving That's that a model the helpful. partially is function equation, that is expenses, decline then cost on revenue recurring of particular, marketing, And job straight definitely controlling Or at well? and Okay. as and in up obviously, to? on side the expense to the sales of just great

Javier Rampolla

reduction experienced we that onetime we in in recorded. So, compensation QX, expense a

that in the is So driving Ben. in decrease marketing basically is QX, what some

Benjamin Haynor

Okay. mean, million... that me? Can kind I is you $X.X for the of quantify

Javier Rampolla

It was about $XXX,XXX.

Benjamin Haynor

the take rest Okay. fall guess offline. the gentlemen, I'll Great. ahead, I

Operator

This you. to for over question-and-answer conference I'd like the our now Joe any remarks. back session. Thank turn concludes Sardano to closing

Joseph Sardano

XX, XXth time to some quarter in through once We'll in when I'd May. and Sensus there. joining in in that first again participating the XX you you for again speak the I being us from held on this interest Healthcare. California March for you Dana mention again Thank thanks Annual to and financial for like with hope we'll the see results your meantime, report your Point, we be Roth today. Conference In of

Operator

concluded. for The attending Thank conference now has presentation. you today's

your now disconnect may You lines.

Sensus Healthcare (SRTS) 8 Feb 242023 Q4 Earnings call transcript